Two core platforms that unlock new possibilities in drug delivery

Focusing on developing transdermal and ocular drug-delivery systems, we break through the limitations of traditional formulations to enhance therapeutic efficacy and patient compliance.

505(b)(2) Pipeline

no. indication Preclinical phase 1 phase 2 phase 3 Nda  Approval
EBP002 Alzheimer's Disease
(7-day patch)
Preclinical
 
Phase 1
 
Phase 2
 
Phase 3
 
NDA
 
Approval
 
EBP006 Pulmonary Hypertension
(1-day patch)
Preclinical

 
Phase 1
 
Phase 2
 
Phase 3
 
NDA
 
Approval
 
EBD008 Posterior Segment Diseases
(Eye Drops)
Preclinical
 
Phase 1
 
Phase 2
 
Phase 3
 
NDA
 
Approval
 
 

High-Barrier Generic Drugs Pipeline

no. indication PRECLINICAL BE study nda APPROVAL
EBP005 Schizophrenia
(1-day patch)
Preclinical
 
BE Study
 
NDA
 
Approval
 
EBP007 Asthma/COPD
(1-day patch)
Preclinical
 
BE Study
 
NDA
 
Approval
 
 

R&D Advantages of Transdermal Drug Delivery Systems:

  • Enhanced drug bioavailability

  • Improved dosing convenience

  • Reduced adverse reactions

  • Expanded therapeutic indications

  • Prolonged drug action duration

By developing new formulations through the 505(b)(2) regulatory pathway, we are able to:

  • Shorten development timelines

  • Reduce R&D risks

  • Accelerate time-to-market